Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery
暂无分享,去创建一个
[1] C. Linhart,et al. Prognostic value of pololike kinase expression in melanomas. , 2000, JAMA.
[2] B. Kuster,et al. Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells , 2014, Cell Research.
[3] K. Strebhardt,et al. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.
[4] J. Peters,et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.
[5] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.
[6] J. Lazo,et al. Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype , 2012, Molecular Cancer Therapeutics.
[7] K. Strebhardt,et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. , 2011, The American journal of pathology.
[8] Valérie Gailus-Durner,et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells , 2011, Nature communications.
[9] T. Karn,et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[10] K. Strebhardt,et al. Silencing of mammalian genes by tetracycline-inducible shRNA expression , 2007, Nature Protocols.
[11] Erich A. Nigg,et al. Polo-like kinases and the orchestration of cell division , 2004, Nature Reviews Molecular Cell Biology.
[12] David M. Glover,et al. Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.
[13] J. Yuan,et al. Polo-like kinase, a novel marker for cellular proliferation. , 1997, The American journal of pathology.
[14] K. Strebhardt,et al. Tumor inhibition by genomically integrated inducible RNAi-cassettes , 2006, Nucleic acids research.
[15] K. Strebhardt,et al. Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. , 2002, Cancer research.
[16] Michael B Yaffe,et al. Proteomic Screen Finds pSer/pThr-Binding Domain Localizing Plk1 to Mitotic Substrates , 2003, Science.
[17] Juping Yuan,et al. A Pan‐Specific Inhibitor of the Polo‐Box Domains of Polo‐like Kinases Arrests Cancer Cells in Mitosis , 2009, Chembiochem : a European journal of chemical biology.
[18] R. Grobholz,et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. , 2000, Pathology, research and practice.
[19] Fa Liu,et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 , 2009, Nature Structural &Molecular Biology.
[20] W. Dai,et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. , 2008, Cancer research.
[21] B. Li,et al. Human Prk Is a Conserved Protein Serine/Threonine Kinase Involved in Regulating M Phase Functions* , 1997, The Journal of Biological Chemistry.
[22] A. Ullrich,et al. Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.
[23] Z. Darżynkiewicz,et al. Cell Cycle Arrest and Apoptosis Induced by Human Polo-Like Kinase 3 Is Mediated through Perturbation of Microtubule Integrity , 2002, Molecular and Cellular Biology.
[24] J. Charron,et al. Role of Plk2 (Snk) in Mouse Development and Cell Proliferation , 2003, Molecular and Cellular Biology.
[25] Z. Yin,et al. Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. , 2013, ACS chemical biology.
[26] M. Rehli,et al. Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages , 2000, Oncogene.
[27] Sven Kappel,et al. Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1 , 2005, Oncogene.
[28] K. Döhner,et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. , 2014, Blood.
[29] Marc C Nicklaus,et al. Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. , 2010, ACS medicinal chemistry letters.
[30] C. McGowan,et al. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways , 2002, Oncogene.
[31] R. Kaufmann,et al. Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease , 2002, Journal of cutaneous pathology.
[32] T. Veenstra,et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. , 2006, Molecular cell.
[33] K. Strebhardt,et al. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. , 2008, Chemistry & biology.
[34] K. Strebhardt,et al. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. , 2008, Analytical biochemistry.
[35] T. Burns,et al. Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed Cells , 2003, Molecular and Cellular Biology.